1. |
Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol, 1983, 7(6): 507-519.
|
2. |
Blay JY, Shen L, Kang YK, et al. Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. Lancet Oncol, 2015, 16(5): 550-560.
|
3. |
Cassier PA, Ducimetière F, Lurkin A, et al. A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region. Br J Cancer, 2010, 103(2): 165-170.
|
4. |
Miettinen M, Lasota J. Gastrointestinal stromal tumors. Gastroenterol Clin North Am, 2013, 42(2): 399-415.
|
5. |
谭至柔, 黄雪, 张瑜红. 46例胃间质瘤的临床分析. 中国现代医学杂志, 2011, 21(33): 4186-4187, 4191.
|
6. |
Pisters PW, Blanke CD, von Mehren M, et al. A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices. Ann Oncol, 2011, 22(11): 2523-2529.
|
7. |
Søreide K, Sandvik OM, Søreide JA, et al. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol, 2016, 40: 39-46.
|
8. |
Wang M, Xu J, Zhang Y, et al. Gastrointestinal stromal tumor: 15-years’ experience in a single center. BMC Surg, 2014, 14: 93.
|
9. |
Yamamoto H, Oda Y. Gastrointestinal stromal tumor: recent advances in pathology and genetics. Pathol Int, 2015, 65(1): 9-18.
|
10. |
Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA, 2012, 307(12): 1265-1272.
|
11. |
Joensuu H, Eriksson M, Sundby Hall K, et al. Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial. J Clin Oncol, 2016, 34(3): 244-250.
|
12. |
Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol, 2008, 39(10): 1411-1419.
|
13. |
尹晓南, 汤苏敏, 尹源, 等. 胃肠间质瘤患者术前PLR、d-NLR值与预后的关系. 四川大学学报: 医学版, 2017, 48(2): 239-243, 275.
|
14. |
胡根, 李威, 邵国益, 等. 术前血小板和淋巴细胞比值对胃间质瘤患者预后的预测价值. 肿瘤防治研究, 2018, 45(7): 479-482.
|
15. |
金鑫, 冯利, 李福广, 等. 血清中性粒细胞/淋巴细胞比值与胃肠间质瘤患者预后的关系及其临床意义. 中国普外基础与临床杂志, 2013, 20(8): 910-914.
|
16. |
Kudou K, Saeki H, Nakashima Y, et al. C-reactive protein/albumin ratio is a poor prognostic factor of esophagogastric junction and upper gastric cancer. J Gastroenterol Hepatol, 2019, 34(2): 355-363.
|
17. |
Liu X, Sun X, Liu J, et al. Preoperative C-reactive protein/albumin ratio predicts prognosis of patients after curative resection for gastric cancer. Transl Oncol, 2015, 8(4): 339-345.
|
18. |
Ni XF, Wu J, Ji M, et al. Effect of C-reactive protein/albumin ratio on prognosis in advanced non-small-cell lung cancer. Asia Pac J Clin Oncol, 2018, 14(6): 402-409.
|
19. |
Toiyama Y, Shimura T, Yasuda H, et al. Clinical burden of C-reactive protein/albumin ratio before curative surgery for patients with gastric cancer. Anticancer Res, 2016, 36(12): 6491-6498.
|
20. |
刘恒昌, 陈羽佳, 许永飞, 等. 术前C反应蛋白与白蛋白比值对胃癌患者预后的影响. 中国实验诊断学, 2018, 22(1): 27-29.
|
21. |
乔乐乐, 王公平, 周博, 等. 胃癌患者术前CRP/Alb比与淋巴结转移相关性的研究. 中国肿瘤临床, 2017, 44(5): 210-213.
|
22. |
Morris-Stiff G, Gomez D, Prasad KR. C-reactive protein in liver cancer surgery. Eur J Surg Oncol, 2008, 34(7): 727-729.
|
23. |
Du J, Hu W, Yang C, et al. C-reactive protein is associated with the development of tongue squamous cell carcinoma. Acta Biochim Biophys Sin (Shanghai), 2018, 50(3): 238-245.
|
24. |
Fiala O, Hosek P, Pesek M, et al. Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed. Neoplasma, 2017, 64(4): 605-610.
|
25. |
Frydenberg H, Thune I, Lofterød T, et al. Pre-diagnostic high-sensitive C-reactive protein and breast cancer risk, recurrence, and survival. Breast Cancer Res Treat, 2016, 155(2): 345-354.
|
26. |
Kim ES, Kim SY, Koh M, et al. C-reactive protein binds to integrin α2 and Fcγ receptor Ⅰ, leading to breast cell adhesion and breast cancer progression. Oncogene, 2018, 37(1): 28-38.
|
27. |
Heneghan HM, Zaborowski A, Fanning M, et al. Prospective study of malabsorption and malnutrition after esophageal and gastric cancer surgery. Ann Surg, 2015, 262(5): 803-807.
|
28. |
Ryan AM, Power DG, Daly L, et al. Cancer-associated mal- nutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. Proc Nutr Soc, 2016, 75(2): 199-211.
|
29. |
Fairclough E, Cairns E, Hamilton J, et al. Evaluation of a modified early warning system for acute medical admissions and comparison with C-reactive protein/albumin ratio as a predictor of patient outcome. Clin Med (Lond), 2009, 9(1): 30-33.
|